abstract |
The present invention is broadly directed to a HER-2 / neu fusion protein, a nucleic acid molecule encoding a HER-2 / neu fusion protein, a viral vector expressing a HER-2 / neu fusion protein, and / (E. G., A vaccine) comprising a nucleic acid molecule encoding a HER-2 / neu fusion protein. The present invention also relates to a method of treating or preventing cancer by inducing or enhancing an immune response to a HER-2 / neu protein, including methods for use in the treatment of malignant tumors associated with HER-2 / neu oncogene . |